Naked monoclonal antibodies or mAbs bind to specific epitopes or target molecules on cells. Therapeutic uses of mAbs have been limited by several factors, including cancer cell specificity, tumor penetration, as well as manufacturing issues. BioAtla’s human CAB mAbs are optimized and expressed in our proprietary CIAO! system. CAB mAbs have a high Therapeutic Index because they are only active under the physiological conditions associated with disease. This unique capability enables development of therapeutics for targets that are also expressed on healthy tissues, while minimizing undesirable side effects.
BioAtla®’s conditionally active Chimeric Antigen Receptor-T cell (CAR-T’s) are drugs engineered by grafting single-chain variable fragments (scFv) from a Conditionally Active Biologic (CAB) antibody with a T cell signaling domain. These fusion molecules trigger T cell recognition and killing of cells expressing the cancer target. The CAB-derived CAR-Ts (CAB-T’s) increase target specificity which assists in decreasing adverse effects and improving therapeutic index.
BioAtla®’s Conditionally Active Bispecific Antibodies (CAB-B’s) are engineered to selectively target two receptors on cancer cells, or provide an alternative way of recruiting immune cells to the cancer tissue.